160 related articles for article (PubMed ID: 8136513)
1. Ondansetron in the treatment of nausea and vomiting. Introduction.
Marschner N
Anticancer Drugs; 1993 Dec; 4 Suppl 2():3-7. PubMed ID: 8136513
[No Abstract] [Full Text] [Related]
2. Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
Kris MG
Important Adv Oncol; 1994; ():165-77. PubMed ID: 8206488
[No Abstract] [Full Text] [Related]
3. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
4. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
5. An overview of ondansetron for chemotherapy-induced nausea and emesis.
San Angel F
J Intraven Nurs; 1993; 16(2):84-9. PubMed ID: 8478782
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
Matera MG; Di Tullio M; Lucarelli C; Casale F; Calabria C; Lampa E; Indolfi P; Rossi F
J Med; 1993; 24(2-3):161-70. PubMed ID: 7691978
[TBL] [Abstract][Full Text] [Related]
7. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
8. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
9. [The management of vomiting and nausea with zofran during the chemotherapy of malignant tumors].
Seliuzhitskiĭ IV; Eliseev SN; Ivanov AI
Voen Med Zh; 1994 Oct; (10):34-6. PubMed ID: 7831851
[No Abstract] [Full Text] [Related]
10. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Simino GP; Marra LP; Andrade EI; Acúrcio Fde A; Reis IA; De Araújo VE; Cherchiglia ML
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1183-94. PubMed ID: 27180992
[TBL] [Abstract][Full Text] [Related]
11. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
12. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
13. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
[TBL] [Abstract][Full Text] [Related]
14. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone in the treatment of nausea and vomiting from cancer chemotherapy.
Winokur SH; Baker JJ; Lokey JL; Price NA; Bowen J
J Med Assoc Ga; 1981 Apr; 70(4):263-4. PubMed ID: 7012258
[No Abstract] [Full Text] [Related]
16. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
Tanimura S; Banba J; Tomoyasu H; Masaki M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
[TBL] [Abstract][Full Text] [Related]
17. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the efficacy of anti-emetic therapy with ondansetron injected intravenously at a daily dose of 8mg (analysis of material)].
Cieślińska A; Pajak K; Ziemba AB; Filipczyk-Cisarz E; Gajewska A
Pol Merkur Lekarski; 1996 Nov; 1(5):337-9. PubMed ID: 9273212
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of two outpatient antiemetic regimens for cancer chemotherapy.
Pruitt BT; Justice RL; Periman P
Tex Med; 1985 Jul; 81(7):44-5. PubMed ID: 3898458
[No Abstract] [Full Text] [Related]
[Next] [New Search]
